Search

Your search keyword '"Rousselot, Philippe"' showing total 1,396 results

Search Constraints

Start Over You searched for: Author "Rousselot, Philippe" Remove constraint Author: "Rousselot, Philippe"
1,396 results on '"Rousselot, Philippe"'

Search Results

1. Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials.

2. Health-related quality of life and symptoms of chronic myeloid leukemia patients after discontinuation of tyrosine kinase inhibitors: results from the EURO-SKI Trial

3. Comets $^{12}$CO$^+$ and $^{13}$CO$^+$ fluorescence models for measuring the $^{12}$C/$^{13}$C isotopic ratio in CO$^+$

4. Inotuzumab Ozogamicin and Low-Intensity Chemotherapy in Older Patients With Newly Diagnosed CD22+ Philadelphia Chromosome–Negative B-Cell Precursor Acute Lymphoblastic Leukemia

5. Correction: Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials

6. The N$_2$ Production Rate in Comet C/2016 R2 (PanSTARRS)

7. NGS-based stratification refines the risk stratification in T-ALL and identifies a very-high-risk subgroup of patients

8. Nilotinib with or without cytarabine for Philadelphia-positive acute lymphoblastic leukemia

9. Interstellar comet 2I/Borisov as seen by MUSE: C$_2$, NH$_2$ and red CN detections

11. BlueMUSE: Project Overview and Science Cases

12. IL-7 receptor expression is frequent in T-cell acute lymphoblastic leukemia and predicts sensitivity to JAK inhibition

13. Targeting RARA overexpression with tamibarotene, a potent and selective RARα agonist, is a novel approach in AML

14. Ponatinib (PON) in patients (pts) with chronic-phase chronic myeloid leukemia (CP-CML) and the T315I mutation (mut): 4-year results from OPTIC.

15. In-depth analysis of responders in the phase 3 PhALLCON trial of ponatinib vs imatinib in newly diagnosed Ph+ ALL.

16. Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial

17. OSSOS. VII. 800+ trans-Neptunian objects - the complete data release

18. Incidence, outcomes, and risk factors of pleural effusion in patients receiving dasatinib therapy for Philadelphia chromosome-positive leukemia

19. Concurrent CDX2 cis-deregulation and UBTF::ATXN7L3 fusion define a novel high-risk subtype of B-cell ALL

21. Significance of Measurable Residual Disease in Adult Philadelphia Chromosome–Positive ALL: A GRAAPH-2014 Study.

22. Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia.

23. Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial

24. Early detection of WT1 measurable residual disease identifies high-risk patients, independent of transplantation in AML

26. Ponatinib vs Imatinib in Frontline Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia

28. The perihelion activity of comet 67P/Churyumov-Gerasimenko as seen by robotic telescopes

29. OSSOS: IV. Discovery of a dwarf planet candidate in the 9:2 resonance with Neptune

31. The Outer Solar System Origins Survey: I. Design and First-Quarter Discoveries

32. Methane clathrates in the Solar System

33. Constitutional DNA Polymorphisms Associated with the Plasma Imatinib Concentration in Chronic Myeloid Leukemia Patients.

35. Management of ALL in Adults: 2023 ELN Recommendations from a European Expert Panel

37. Diagnosis, Prognostic Factors and Assessment of ALL in Adults: 2023 ELN Recommendations from a European Expert Panel

38. Supplementary Figure S1 from PHF6-altered T-ALL Harbor Epigenetic Repressive Switch at Bivalent Promoters and Respond to 5-Azacitidine and Venetoclax

39. Supplementary Table S2 from PHF6-altered T-ALL Harbor Epigenetic Repressive Switch at Bivalent Promoters and Respond to 5-Azacitidine and Venetoclax

40. Data from PHF6-altered T-ALL Harbor Epigenetic Repressive Switch at Bivalent Promoters and Respond to 5-Azacitidine and Venetoclax

41. Dasatinib in imatinib‐resistant or ‐intolerant chronic‐phase, chronic myeloid leukemia patients: 7‐year follow‐up of study CA180‐034

42. Distant activity of comet C/2002 VQ94 (LINEAR): optical spectrophotometric monitoring between 8.4 and 16.8 au from the Sun

43. The dual origin of the nitrogen deficiency in comets: selective volatile trapping in the nebula and postaccretion radiogenic heating

44. The remarkable surface homogeneity of the Dawn mission target (1) Ceres

45. The Canada-France Ecliptic Plane Survey - Full Data Release: The orbital structure of the Kuiper belt

47. Oncogenetic-Driven Targeted Therapy for Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia : A French ALL-Target Observatory Report

48. POSTER: CML-313 Post Hoc Analysis of Patient Responses by T315I Mutation Status From the 3-Year Update of the OPTIC Trial: A Dose-Optimization Study of 3 Starting Doses of Ponatinib

49. POSTER: ALL-300 First Report of PhALLCON: A Phase 3 Study Comparing Ponatinib Versus Imatinib in Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphocytic Leukemia

50. CML-313 Post Hoc Analysis of Patient Responses by T315I Mutation Status From the 3-Year Update of the OPTIC Trial: A Dose-Optimization Study of 3 Starting Doses of Ponatinib

Catalog

Books, media, physical & digital resources